Abstract
‘Globesity’ is a descriptive term for the obesity epidemic now facing the U.S. and indeed, the world. Hyperphagia (i.e. overeating) can lead to metabolic syndrome which in turn can lead to Type 2 diabetes mellitus, heart disease, stroke and some cancers. The World Health Organization even states that more people die each year from the consequences of obesity than from hunger. Something must be done to stem the tsunami of obesity and its resultant medical complications. Our work and that of others suggests that new obesity treatments and anti-obesity medications should be based on those already successful in treating other addictions. This paper looks at empirical evidence linking addictions to food and to drugs such as tobacco, alcohol, cannabis, amphetamines, and cocaine. Hypotheses are put forth as to why hyperphagia is so difficult to treat. Additionally, prenatal programming for addiction is explored. Lessons from successful drug treatment are elucidated and potential pharmaceutical targets for hyperphagia and obesity are suggested.
Keywords: Hyperphagia, metabolic syndrome, Type 2 diabetes mellitus, withdrawal, dopamine, reward pathways, Globesity, pandemic, anorexia, hyperlipidemia, orexin, leptin, deprivation, Dexfenfluramine, fluoxetine, phenylpropanolamine, naltrexone, detoxification, neurobiological
Current Pharmaceutical Design
Title: Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs
Volume: 17 Issue: 12
Author(s): Paula J. Edge and Mark S. Gold
Affiliation:
Keywords: Hyperphagia, metabolic syndrome, Type 2 diabetes mellitus, withdrawal, dopamine, reward pathways, Globesity, pandemic, anorexia, hyperlipidemia, orexin, leptin, deprivation, Dexfenfluramine, fluoxetine, phenylpropanolamine, naltrexone, detoxification, neurobiological
Abstract: ‘Globesity’ is a descriptive term for the obesity epidemic now facing the U.S. and indeed, the world. Hyperphagia (i.e. overeating) can lead to metabolic syndrome which in turn can lead to Type 2 diabetes mellitus, heart disease, stroke and some cancers. The World Health Organization even states that more people die each year from the consequences of obesity than from hunger. Something must be done to stem the tsunami of obesity and its resultant medical complications. Our work and that of others suggests that new obesity treatments and anti-obesity medications should be based on those already successful in treating other addictions. This paper looks at empirical evidence linking addictions to food and to drugs such as tobacco, alcohol, cannabis, amphetamines, and cocaine. Hypotheses are put forth as to why hyperphagia is so difficult to treat. Additionally, prenatal programming for addiction is explored. Lessons from successful drug treatment are elucidated and potential pharmaceutical targets for hyperphagia and obesity are suggested.
Export Options
About this article
Cite this article as:
J. Edge Paula and S. Gold Mark, Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs, Current Pharmaceutical Design 2011; 17 (12) . https://dx.doi.org/10.2174/138161211795656738
DOI https://dx.doi.org/10.2174/138161211795656738 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Review on Experimental Methods for Diabetes Induction and Therapeutic Efficacy of Anti-diabetic Drug Loaded Nanoformulation
Current Drug Therapy Group A Streptococcal Vaccine Candidates based on the Conserved Conformational Epitope from M Protein
Drug Delivery Letters The Central Role of Angiotensin I-Converting Enzyme in Vertebrate Pathophysiology
Current Topics in Medicinal Chemistry Lipid Profile Results after Cardiovascular Prevention Programme: Euroaction Model in Spain
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacogenomics in Drug Induced Liver Injury
Current Drug Metabolism The Effects of Medications Used for the Management of Dyslipidemia on Postprandial Lipemia
Current Medicinal Chemistry ATP Binding Cassette Transporter A1 (ABCA1) Associated Proteins:Potential Drug Targets in the Metabolic Syndrome and Atherosclerotic Disease?
Current Pharmaceutical Biotechnology PPARγ Agonists: Beneficial Effect on Blood Pressure Beyond Glycemic Control?
Current Hypertension Reviews Management of Dyslipidemia in the Metabolic Syndrome
Cardiovascular & Hematological Disorders-Drug Targets Diagnostic use of Adenosine for Atrial Flutter with Regular Tachycardia
New Emirates Medical Journal Sauropus androgynus Leaves for Health Benefits: Hype and the Science
The Natural Products Journal Monitoring Calcific Aortic Valve Disease: The Role of Biomarkers
Current Medicinal Chemistry Meet our Editorial Board Member
Cardiovascular & Hematological Agents in Medicinal Chemistry Evaluation of Gene and Cell-Based Therapies for Cardiac Regeneration
Current Stem Cell Research & Therapy Is Renalase a Novel Player in Catecholaminergic Signaling? The Mystery of the Catalytic Activity of an Intriguing New Flavoenzyme
Current Pharmaceutical Design Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making
Current Pharmaceutical Biotechnology Editorial: Bioengineering, Clinical and Therapeutical Trends in Transcatheter Aortic Valve Implantation
Current Pharmaceutical Design Prevention of Sudden Cardiac Death in Hemodialysis Patients
Cardiovascular & Hematological Disorders-Drug Targets Preface
Letters in Drug Design & Discovery Potential of Resveratrol in Preventing the Development of Heart Failure
Current Chemical Biology